[
  {
    "_id": "5e31acdce6807b4b7b79560c",
    "title": "CLASS 4 DRUG ALERT: For information, Dr. Reddy’s Laboratories (UK) Ltd, Finasteride 5mg tablets",
    "slug": "class-4-drug-alert-for-information-dr-reddys-laboratories-uk-ltd-finasteride-5mg-tablets",
    "url": "https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=103389",
    "shortSummary": "Patient information leaflets for specific batches are missing the warnings relating to mood alteration and depression. HCPs are asked to ensure that patients are aware of the missing information and the current SmPC should be included when dispensing these batches.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/class-4-drug-alert-for-information-dr-reddys-laboratories-uk-ltd-finasteride-5mg-tablets.html",
    "source": {
      "_id": "5e283dc83b5e750642253c88",
      "title": "Medicines and Healthcare products Regulatory Agency"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253efa",
        "key": "67588b95-7ebb-4283-99aa-a6bddfa7ea43",
        "title": "Renal and urologic disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ef0",
        "key": "9e36e9bc-220b-41d6-9d5c-600921d39e72",
        "title": "Mental health and illness",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f24",
      "title": "Safety alerts",
      "key": "mas_evidence_types:Safety%20alerts",
      "broaderTitle": "Safety alerts"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:24:36.761Z",
    "createdAt": "2020-01-29T16:03:40.743Z"
  },
  {
    "_id": "5e31adc5e6807b4b7b79560d",
    "title": "First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations",
    "slug": "first-trimester-pregnancy-exposure-to-modafinil-and-risk-of-congenital-malformations",
    "url": "https://jamanetwork.com/journals/jama/fullarticle/2759460",
    "shortSummary": "Danish Health Registry analysis (49 pregnancies exposed to modafinil and 828,644 unexposed) found that modafinil was associated with significantly more congenital defects than no exposure (OR 3.4, 95% CI 1.5-7.4), or methylphenidate exposure (3.0, 1.2-7.4)",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/first-trimester-pregnancy-exposure-to-modafinil-and-risk-of-congenital-malformations.html",
    "source": {
      "_id": "5e283dc83b5e750642253c2c",
      "title": "Journal of the American Medical Association"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253ef2",
        "key": "793637c7-9615-42b1-905c-4827a6fab04c",
        "title": "Neurological disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ef4",
        "key": "06944b54-b666-4f00-8c80-74eca60efcbc",
        "title": "Obstetrics and gynaecology",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f1c",
      "title": "Primary research - Other primary research",
      "key": "mas_evidence_types:Other%20primary%20research",
      "broaderTitle": "Primary research"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:25:48.825Z",
    "createdAt": "2020-01-29T16:07:33.248Z"
  },
  {
    "_id": "5e31aef7e6807b4b7b79560f",
    "title": "Maternity services survey 2019",
    "slug": "maternity-services-survey-2019",
    "url": "https://www.cqc.org.uk/publications/surveys/maternity-services-survey-2019",
    "shortSummary": "This report found positive upward trends in areas such as feeding choices and partner involvement, however in line with previous years, results still indicate poorer experience of care for many women postnatally vs antenatal care and care during labour.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/maternity-services-survey-2019.html",
    "source": {
      "_id": "5e283dc83b5e750642253a3d",
      "title": "Care Quality Commission"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253ef4",
        "key": "06944b54-b666-4f00-8c80-74eca60efcbc",
        "title": "Obstetrics and gynaecology",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:26:13.105Z",
    "createdAt": "2020-01-29T16:12:39.228Z"
  },
  {
    "_id": "5e31af84e6807b4b7b795610",
    "title": "Adapting Lean methods to facilitate stakeholder engagement and co-design in healthcare",
    "slug": "adapting-lean-methods-to-facilitate-stakeholder-engagement-and-co-design-in-healthcare",
    "url": "https://www.bmj.com/content/368/bmj.m35",
    "shortSummary": "This review highlights the Lean approach for quality improvement, and how it can be implemented in healthcare, which has a multistakeholder view of value (i.e. clinicians and management as well as patients), rather than targeting improvements just for customers.",
    "comment": "",
    "resourceLinks": "<p><a href=\"https://www.bmj.com/content/368/bmj.m35\">Link (s)</a></p>",
    "commentUrl": "https://www.medicinesresources.nhs.uk/adapting-lean-methods-to-facilitate-stakeholder-engagement-and-co-design-in-healthcare.html",
    "source": {
      "_id": "5e283dc83b5e750642253a11",
      "title": "British Medical Journal"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253ef9",
        "key": "5a18afa9-e3b0-4f40-a131-2bd007c6bab7",
        "title": "Policy, Commissioning and Managerial",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Policy",
      "key": "mas_evidence_types:Policy",
      "broaderTitle": "Policy"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T16:15:58.274Z",
    "createdAt": "2020-01-29T16:15:00.276Z"
  },
  {
    "_id": "5e31b05ae6807b4b7b795611",
    "title": "Manufacturers report positive results for ruxolitinib cream in atopic dermatitis",
    "slug": "manufacturers-report-positive-results-for-ruxolitinib-cream-in-atopic-dermatitis",
    "url": "https://www.biospace.com/article/incyte-s-ruxolitinib-hits-mark-in-dermatitis-trial/",
    "shortSummary": "Results from the Phase III TruR-AD2 trial found that ruxolitinib was superior to placebo vehicle by at least 2 points in the Investigator’s Global Assessment Treatment Success score. The manufacturers have not yet made a submission for regulatory review for this treatment.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/manufacturers-report-positive-results-for-ruxolitinib-cream-in-atopic-dermatitis.html",
    "source": {
      "_id": "5e283dc83b5e7506422539c4",
      "title": "Biospace Inc."
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253efd",
        "key": "3665f6cd-25c6-4c1b-9a81-3f61a93a68e4",
        "title": "Skin disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253edd",
        "key": "023caa1d-543e-4cd4-a89d-8eaa2c0ec513",
        "title": "Allergy and immunology",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:28:35.916Z",
    "createdAt": "2020-01-29T16:18:34.470Z"
  },
  {
    "_id": "5e31b2c7e6807b4b7b795614",
    "title": "Linking risk factors and outcomes in autism spectrum disorder: is there evidence for resilience?",
    "slug": "linking-risk-factors-and-outcomes-in-autism-spectrum-disorder-is-there-evidence-for-resilience",
    "url": "https://www.bmj.com/content/368/bmj.l6880",
    "shortSummary": "This review discusses advances in understanding of the causal pathways leading to autism and overlapping neurodevelopmental conditions. It highlights recent improvements in early identification, but that key knowledge gaps remain.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/linking-risk-factors-and-outcomes-in-autism-spectrum-disorder-is-there-evidence-for-resilience.html",
    "source": {
      "_id": "5e283dc83b5e750642253a11",
      "title": "British Medical Journal"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eee",
        "key": "fb8766ce-2c88-4db6-a56d-906ee2ee2603",
        "title": "Learning disabilities",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ef7",
        "key": "141aeb17-6599-4c05-a6fe-a64e5b994141",
        "title": "Paediatric and neonatal medicine",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:32:19.531Z",
    "createdAt": "2020-01-29T16:28:55.821Z"
  },
  {
    "_id": "5e31b337e6807b4b7b795615",
    "title": "Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations",
    "slug": "tumour-lysis-syndrome-in-patients-with-chronic-lymphocytic-leukaemia-treated-with-bcl-2-inhibitors-risk-factors-prophylaxis-and-treatment-recommendations",
    "url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30253-4/fulltext",
    "shortSummary": "This viewpoint discusses the pathophysiology, risk factors, monitoring, changes in laboratory parameters, and clinical manifestations of tumour lysis syndrome, and the prophylaxis and treatments available for this complication.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/tumour-lysis-syndrome-in-patients-with-chronic-lymphocytic-leukaemia-treated-with-bcl-2-inhibitors-risk-factors-prophylaxis-and-treatment-recommendations.html",
    "source": {
      "_id": "5e283dc93b5e750642253e54",
      "title": "The Lancet Haematology"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253edf",
        "key": "8f13726e-5635-471f-ad3c-fc910a6ac2b1",
        "title": "Cancers",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253eeb",
        "key": "6c632dfa-b6a2-4b3a-ac31-4c4ebe22a2d2",
        "title": "Haematological disorders",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:32:56.102Z",
    "createdAt": "2020-01-29T16:30:47.415Z"
  },
  {
    "_id": "5e31b3c7e6807b4b7b795616",
    "title": "Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation",
    "slug": "prophylaxis-and-management-of-graft-versus-host-disease-after-stem-cell-transplantation-for-haematological-malignancies-updated-consensus-recommendations-of-the-european-society-for-blood-and-marrow-transplantation",
    "url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30256-X/fulltext",
    "shortSummary": "Key updates in these guidelines include recommendations for lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations and the addition of newer treatment options for steroid-refractory acute and chronic GVHD.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/prophylaxis-and-management-of-graft-versus-host-disease-after-stem-cell-transplantation-for-haematological-malignancies-updated-consensus-recommendations-of-the-european-society-for-blood-and-marrow-transplantation.html",
    "source": {
      "_id": "5e283dc93b5e750642253e54",
      "title": "The Lancet Haematology"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eeb",
        "key": "6c632dfa-b6a2-4b3a-ac31-4c4ebe22a2d2",
        "title": "Haematological disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253edf",
        "key": "8f13726e-5635-471f-ad3c-fc910a6ac2b1",
        "title": "Cancers",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:33:06.445Z",
    "createdAt": "2020-01-29T16:33:11.587Z"
  },
  {
    "_id": "5e31b430e6807b4b7b795617",
    "title": "Advances and challenges in stroke rehabilitation",
    "slug": "advances-and-challenges-in-stroke-rehabilitation",
    "url": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30415-6/fulltext",
    "shortSummary": "This review highlights that substantial advances are yet to be made in stroke rehabilitation practice. It concludes that although stroke rehabilitation research strives for better trials, rehabilitation practices continue to help patients regain independence after stroke.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/advances-and-challenges-in-stroke-rehabilitation.html",
    "source": {
      "_id": "5e283dc93b5e750642253e57",
      "title": "The Lancet Neurology"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eff",
        "key": "d0ea592c-932a-462f-b206-cf454e40fa20",
        "title": "Stroke",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:33:26.018Z",
    "createdAt": "2020-01-29T16:34:56.608Z"
  },
  {
    "_id": "5e31b491e6807b4b7b795618",
    "title": "Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer – appraisal consultation document",
    "slug": "lorlatinib-for-treating-alk-positive-advanced-non-small-cell-lung-cancer-appraisal-consultation-document",
    "url": "https://www.nice.org.uk/guidance/indevelopment/gid-ta10317/consultation/html-content-2",
    "shortSummary": "In DRAFT guidance NICE does not recommend lorlatinib for ALK+ve advanced NSCLC after progression on alectinib, ceritinib or crizotinib as the most likely cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/lorlatinib-for-treating-alk-positive-advanced-non-small-cell-lung-cancer-appraisal-consultation-document.html",
    "source": {
      "_id": "5e283dc83b5e750642253ccc",
      "title": "National Institute for Health and Care Excellence"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253edf",
        "key": "8f13726e-5635-471f-ad3c-fc910a6ac2b1",
        "title": "Cancers",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253efb",
        "key": "eb492904-ca53-4abb-9e61-15871d3b1cb9",
        "title": "Respiratory disorders",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-28T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:33:45.691Z",
    "createdAt": "2020-01-29T16:36:33.945Z"
  },
  {
    "_id": "5e31b509e6807b4b7b795619",
    "title": "Wuhan novel coronavirus – RPS resource page",
    "slug": "wuhan-novel-coronavirus-rps-resource-page",
    "url": "https://www.rpharms.com/resources/pharmacy-guides/wuhan-novel-coronavirus",
    "shortSummary": "This new resource page highlights five key facts for pharmacy teams on the Wuhan novel coronavirus, and links to the various national documents and communications on this (e.g. PHE).",
    "comment": "<p>The FDA have also published a resource page from the US perspective, including a situation summary, Frequently Asked Questions, and a background to the condition.</p>",
    "resourceLinks": "<p><a href=\"https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/novel-coronavirus-2019-ncov\">FDA resource page</a></p>",
    "commentUrl": "https://www.medicinesresources.nhs.uk/wuhan-novel-coronavirus-rps-resource-page.html",
    "source": {
      "_id": "5e283dc93b5e750642253dd4",
      "title": "Royal Pharmaceutical Society"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eec",
        "key": "f48a5fc4-8228-47ec-ba84-e6c8e22ded59",
        "title": "Infection and infectious diseases",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253f01",
        "key": "e52e495c-c963-43fc-92f4-47061994e034",
        "title": "Travel medicine",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:34:37.544Z",
    "createdAt": "2020-01-29T16:38:33.555Z"
  },
  {
    "_id": "5e31b5e2e6807b4b7b79561b",
    "title": "Taskforce Charter: National Quality Improvement Taskforce for children and young people’s mental health inpatient services",
    "slug": "taskforce-charter-national-quality-improvement-taskforce-for-children-and-young-peoples-mental-health-inpatient-services-1",
    "url": "https://www.england.nhs.uk/publication/taskforce-charter-children-young-peoples-mental-health/",
    "shortSummary": "This document provides details of NHS England’s vision for mental health, learning disability, and autism inpatient services to be delivered to the consistently high standard that children and young people deserve.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/taskforce-charter-national-quality-improvement-taskforce-for-children-and-young-peoples-mental-health-inpatient-services.html",
    "source": {
      "_id": "5e283dc83b5e750642253d01",
      "title": "NHS England"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253ef0",
        "key": "9e36e9bc-220b-41d6-9d5c-600921d39e72",
        "title": "Mental health and illness",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ef7",
        "key": "141aeb17-6599-4c05-a6fe-a64e5b994141",
        "title": "Paediatric and neonatal medicine",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-24T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:35:11.221Z",
    "createdAt": "2020-01-29T16:42:10.152Z"
  },
  {
    "_id": "5e31b697e6807b4b7b79561c",
    "title": "Ticagrelor hits primary endpoint in the THALES Phase III trial for use in stroke",
    "slug": "ticagrelor-hits-primary-endpoint-in-the-thales-phase-iii-trial-for-use-in-stroke",
    "url": "http://www.pharmatimes.com/news/brilinta_hits_endpoint_in_late-stage_stroke_trial_1323581",
    "shortSummary": "In this study, the manufacturers report that ticagrelor 90 mg twice daily plus aspirin for 30 days showed a statistically significant and clinically meaningful reduction in the risk of stroke and death vs aspirin alone.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/ticagrelor-hits-primary-endpoint-in-the-thales-phase-iii-trial-for-use-in-stroke.html",
    "source": {
      "_id": "5e283dc93b5e750642253d73",
      "title": "PharmaTimes"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eff",
        "key": "d0ea592c-932a-462f-b206-cf454e40fa20",
        "title": "Stroke",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:35:28.021Z",
    "createdAt": "2020-01-29T16:45:11.510Z"
  },
  {
    "_id": "5e31b715e6807b4b7b79561d",
    "title": "RMOC Shared Care Guidance: Consultation running",
    "slug": "rmoc-shared-care-guidance-consultation-running",
    "url": "https://www.sps.nhs.uk/articles/rmoc-shared-care-guidance-consultation-running-until-7-2-2020/",
    "shortSummary": "RMOC North is seeking comments on the draft Shared Care Guidance V2 document which includes; a definition of shared care, letter templates to support shared care communications, and a list of medicines deemed suitable for shared care. The deadline for comments is 4th February.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/rmoc-shared-care-guidance-consultation-running.html",
    "source": {
      "_id": "5e283dc93b5e750642253e13",
      "title": "Specialist Pharmacy Service"
    },
    "specialities": [],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f17",
      "title": "Media and commentaries",
      "key": "mas_evidence_types:Media%20and%20commentaries",
      "broaderTitle": "Media and commentaries"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:35:44.621Z",
    "createdAt": "2020-01-29T16:47:17.584Z"
  },
  {
    "_id": "5e31b7a8e6807b4b7b79561e",
    "title": "Colorectal cancer updated quality standard – update (QS20)",
    "slug": "colorectal-cancer-updated-quality-standard-update-qs20",
    "url": "https://www.nice.org.uk/guidance/qs20",
    "shortSummary": "This quality standard has been updated following publication of new NCIE guidance for colorectal cancer (NG151).  Statements 1, 2, 3, 5 and 7 were removed because they are no longer in line with the NICE guideline, and statements 4 and 6 were amended.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/colorectal-cancer-updated-quality-standard-update-qs20.html",
    "source": {
      "_id": "5e283dc83b5e750642253ccc",
      "title": "National Institute for Health and Care Excellence"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253ee9",
        "key": "324813be-a93e-485a-89bd-8464e4a412e0",
        "title": "Gastrointestinal disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253edf",
        "key": "8f13726e-5635-471f-ad3c-fc910a6ac2b1",
        "title": "Cancers",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f22",
      "title": "Other evidence - Quality measures",
      "key": "mas_evidence_types:Quality%20measures",
      "broaderTitle": "Other evidence"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:36:07.495Z",
    "createdAt": "2020-01-29T16:49:44.212Z"
  },
  {
    "_id": "5e31b86ee6807b4b7b79561f",
    "title": "NIHR Signal: Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury and reduces deaths",
    "slug": "nihr-signal-tranexamic-acid-is-safe-to-use-following-mild-to-moderate-traumatic-brain-injury-and-reduces-deaths",
    "url": "https://discover.dc.nihr.ac.uk/content/signal-000870/tranexamic-acid-following-mild-to-moderate-traumatic-brain-injury-is-safe-and-reduces-deaths",
    "shortSummary": "Expert commentary is provided for an RCT (n=12,737) which found fewer deaths from mild-moderate head injury in those given tranexamic acid vs placebo (5.8% vs 7.5%, RR 0.78, p<0.05), though the young age of the cohort raises concerns about applying the findings to older patients.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/nihr-signal-tranexamic-acid-is-safe-to-use-following-mild-to-moderate-traumatic-brain-injury-and-reduces-deaths.html",
    "source": {
      "_id": "5e283dc83b5e750642253d1d",
      "title": "NIHR Dissemination Centre"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253eeb",
        "key": "6c632dfa-b6a2-4b3a-ac31-4c4ebe22a2d2",
        "title": "Haematological disorders",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ee5",
        "key": "ea782323-1ebb-44d6-ba9e-2d97e78b8cf5",
        "title": "Emergency medicine and urgent care",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ef2",
        "key": "793637c7-9615-42b1-905c-4827a6fab04c",
        "title": "Neurological disorders",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f0f",
      "title": "Evidence summary - Evidence summaries",
      "key": "mas_evidence_types:Evidence%20summaries",
      "broaderTitle": "Evidence summary"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:36:57.042Z",
    "createdAt": "2020-01-29T16:53:02.573Z"
  },
  {
    "_id": "5e31b9abe6807b4b7b795621",
    "title": "NIHR Signal: Uptake of shingles vaccination is more likely if proactively offered in primary care",
    "slug": "nihr-signal-uptake-of-shingles-vaccination-is-more-likely-if-proactively-offered-in-primary-care",
    "url": "https://discover.dc.nihr.ac.uk/content/signal-000865/shingles-vaccination-uptake-more-likely-if-proactively-offered",
    "shortSummary": "Expert commentary is provided for a study (n=2,530) which found that people were more than twice as likely to have had the shingles vaccine if it was offered by a GP or nurse. It also reported that awareness of the vaccine could be improved through more effective campaigns.",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/nihr-signal-uptake-of-shingles-vaccination-is-more-likely-if-proactively-offered-in-primary-care.html",
    "source": {
      "_id": "5e283dc83b5e750642253d1d",
      "title": "NIHR Dissemination Centre"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253f02",
        "key": "5a1195de-2f22-4ac5-8ccc-b5b3d292da87",
        "title": "Vaccination",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f0f",
      "title": "Systematic review - Systematic reviews",
      "key": "mas_evidence_types:Systematic%20reviews",
      "broaderTitle": "Systematic review"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:38:52.985Z",
    "createdAt": "2020-01-29T16:58:19.553Z"
  },
  {
    "_id": "5e31a897e6807b4b7b795609",
    "title": "Colorectal cancer – guidance (NG151)",
    "slug": "colorectal-cancer-guidance-ng151-1",
    "url": "https://www.nice.org.uk/guidance/ng151",
    "shortSummary": "This guideline covers managing colorectal (bowel) cancer in people aged 18 and over and aims to improve quality of life and survival for adults with this disease through management of local disease and management of secondary tumours (metastatic disease).",
    "comment": "",
    "resourceLinks": "",
    "commentUrl": "https://www.medicinesresources.nhs.uk/colorectal-cancer-guidance-ng151.html",
    "source": {
      "_id": "5e283dc83b5e750642253ccc",
      "title": "National Institute for Health and Care Excellence"
    },
    "specialities": [
      {
        "_id": "5e283dc93b5e750642253edf",
        "key": "8f13726e-5635-471f-ad3c-fc910a6ac2b1",
        "title": "Cancers",
        "__v": 0
      },
      {
        "_id": "5e283dc93b5e750642253ee9",
        "key": "324813be-a93e-485a-89bd-8464e4a412e0",
        "title": "Gastrointestinal disorders",
        "__v": 0
      }
    ],
    "evidenceType": {
      "_id": "5e283dc93b5e750642253f13",
      "title": "Guidance and advice - Guidance",
      "key": "mas_evidence_types:Guidance",
      "broaderTitle": "Guidance and advice"
    },
    "publicationDate": "2020-01-29T00:00:00.000Z",
    "updatedAt": "2020-01-29T17:25:18.337Z",
    "createdAt": "2020-01-29T15:45:27.246Z"
  }
]